BR112022008287A2 - Métodos de tratamento usando um modulador de mtorc1 - Google Patents
Métodos de tratamento usando um modulador de mtorc1Info
- Publication number
- BR112022008287A2 BR112022008287A2 BR112022008287A BR112022008287A BR112022008287A2 BR 112022008287 A2 BR112022008287 A2 BR 112022008287A2 BR 112022008287 A BR112022008287 A BR 112022008287A BR 112022008287 A BR112022008287 A BR 112022008287A BR 112022008287 A2 BR112022008287 A2 BR 112022008287A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment methods
- mtorc1
- modulator
- mtorc1 modulator
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Abstract
MÉTODOS DE TRATAMENTO USANDO UM MODULADOR DE MTORC1. A presente invenção refere-se a métodos, composições e formas de dosagem unitária úteis para modular seletivamente a atividade de mTORC1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962929449P | 2019-11-01 | 2019-11-01 | |
PCT/US2020/058475 WO2021087432A1 (en) | 2019-11-01 | 2020-11-02 | Methods of treatment using an mtorc1 modulator |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022008287A2 true BR112022008287A2 (pt) | 2022-07-26 |
Family
ID=75716349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022008287A BR112022008287A2 (pt) | 2019-11-01 | 2020-11-02 | Métodos de tratamento usando um modulador de mtorc1 |
Country Status (11)
Country | Link |
---|---|
US (2) | US11723890B2 (pt) |
EP (1) | EP4051259A4 (pt) |
JP (1) | JP2022554276A (pt) |
CN (1) | CN114786660A (pt) |
AU (1) | AU2020376950A1 (pt) |
BR (1) | BR112022008287A2 (pt) |
CA (1) | CA3156436A1 (pt) |
IL (1) | IL292612A (pt) |
MX (1) | MX2022005215A (pt) |
TW (1) | TW202131910A (pt) |
WO (1) | WO2021087432A1 (pt) |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4346110A (en) | 1981-06-01 | 1982-08-24 | Merrell Toraude Et Compagnie | Method for treating depression |
GB8827885D0 (en) | 1988-11-30 | 1989-01-05 | Wellcome Found | Novel heterocyclic pesticidal compounds |
US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
DE19623142A1 (de) | 1996-06-10 | 1997-12-11 | Huels Chemische Werke Ag | Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung |
PL331854A1 (en) | 1996-08-28 | 1999-08-16 | Procter & Gamble | Phosphinamides as inhibitors of metaloprotease matrix |
US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
WO1999055688A1 (en) | 1998-04-27 | 1999-11-04 | Warner-Lambert Company | Substituted diarylalkyl amides as calcium channel antagonists |
HUP0104266A2 (hu) | 1998-11-04 | 2002-03-28 | Montell Technology Company Bv. | Komponensek és katalizátorok olefinek polimerizálására |
US20030203900A1 (en) | 1999-05-18 | 2003-10-30 | Martin Quibell | Cysteine protease inhibitors |
CA2445395C (en) | 2001-04-27 | 2010-03-30 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent comprising the same as effective component |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
SI1536827T1 (sl) | 2002-08-14 | 2009-06-30 | Silence Therapeutics Ag | Uporaba protein-kinaze n beta |
US6787664B2 (en) | 2002-09-17 | 2004-09-07 | Warner-Lambert Company Llc | Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs |
AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
JP2006523237A (ja) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ, インコーポレイテッド | Pi−3キナーゼインヒビタープロドラッグ |
KR101168441B1 (ko) | 2003-05-30 | 2012-07-25 | 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 | 암 또는 바이러스 질환의 치료를 위한 삼복소환 화합물,조성물 및 방법 |
AU2004257167B2 (en) | 2003-07-03 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
PL3153514T3 (pl) | 2004-05-13 | 2022-01-10 | Icos Corporation | Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta |
BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
AU2006242851A1 (en) | 2005-02-18 | 2006-11-09 | Centre National De La Recherche Scientifique (C.N.R.S.) | Diastereoisomers of 4-hydroxyisoleucine and uses thereof |
CN101175738B (zh) | 2005-05-12 | 2010-10-27 | 雅培制药有限公司 | 细胞凋亡促进剂 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
DK1931645T3 (da) | 2005-10-07 | 2014-09-29 | Exelixis Inc | N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase |
BR122021011787B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
DK2455382T3 (da) | 2005-12-13 | 2017-01-02 | Incyte Holdings Corp | Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
DE602007007323D1 (de) | 2006-04-26 | 2010-08-05 | Hoffmann La Roche | Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor |
CA2661220A1 (en) | 2006-08-21 | 2008-02-28 | James R. Hauske | Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
TWI397418B (zh) | 2006-10-10 | 2013-06-01 | Otsuka Pharma Co Ltd | 抗憂鬱劑 |
KR101737753B1 (ko) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
TW200902019A (en) | 2007-04-26 | 2009-01-16 | Ono Pharmaceutical Co | Dicyclic heterocyclic compound |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
US8445686B2 (en) | 2007-08-27 | 2013-05-21 | Abbvie Inc. | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
EA017218B1 (ru) | 2008-03-11 | 2012-10-30 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak-киназ |
US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
JP2012530115A (ja) | 2009-06-19 | 2012-11-29 | レツク・フアーマシユーテイカルズ・デー・デー | 置換アルカ−1−インを経由するα−アミノボロン酸誘導体の調製のための新規な合成経路 |
EP2459182B1 (en) | 2009-07-30 | 2017-09-06 | University of Zürich | Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
BR112012033770A2 (pt) | 2010-06-30 | 2016-11-22 | Fujifilm Corp | novo derivado de nicotinamida ou sal do mesmo |
CN102464701B (zh) | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
WO2013142229A1 (en) | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
NZ631523A (en) | 2012-08-06 | 2017-03-31 | Pitney Pharmaceuticals Pty Ltd | Compounds for the treatment of mtor pathway related diseases |
US20160002159A1 (en) | 2013-02-13 | 2016-01-07 | Neal ZONDLO | Perfluoro-tert-butyl hydroxyproline |
WO2014201111A1 (en) | 2013-06-14 | 2014-12-18 | The Brigham And Women's Hospital, Inc. | Treatment of mtor hyperactive related diseases and disorders |
SG11201803099SA (en) | 2015-10-23 | 2018-05-30 | Navitor Pharm Inc | Modulators of sestrin-gator2 interaction and uses thereof |
US20180327364A1 (en) | 2015-11-13 | 2018-11-15 | Brandeis University | Mtor inhibitors and methods of use thereof |
CN116370448A (zh) | 2017-04-26 | 2023-07-04 | 纳维托制药有限公司 | Sestrin-gator2相互作用的调节剂及其用途 |
US10653652B2 (en) | 2018-02-08 | 2020-05-19 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction |
EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | POLYMORPHIC COMPOUNDS AND USES THEREOF |
JP6689441B1 (ja) | 2019-11-01 | 2020-04-28 | エヌ・ティ・ティ・コミュニケーションズ株式会社 | 電子マネー管理システムおよび電子マネー管理方法 |
-
2020
- 2020-11-02 WO PCT/US2020/058475 patent/WO2021087432A1/en active Application Filing
- 2020-11-02 MX MX2022005215A patent/MX2022005215A/es unknown
- 2020-11-02 BR BR112022008287A patent/BR112022008287A2/pt unknown
- 2020-11-02 CN CN202080083322.0A patent/CN114786660A/zh active Pending
- 2020-11-02 EP EP20882523.2A patent/EP4051259A4/en active Pending
- 2020-11-02 IL IL292612A patent/IL292612A/en unknown
- 2020-11-02 CA CA3156436A patent/CA3156436A1/en active Pending
- 2020-11-02 US US17/086,639 patent/US11723890B2/en active Active
- 2020-11-02 TW TW109138111A patent/TW202131910A/zh unknown
- 2020-11-02 JP JP2022525289A patent/JP2022554276A/ja active Pending
- 2020-11-02 AU AU2020376950A patent/AU2020376950A1/en active Pending
-
2023
- 2023-06-29 US US18/216,307 patent/US20240041811A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4051259A4 (en) | 2023-11-22 |
MX2022005215A (es) | 2022-06-08 |
JP2022554276A (ja) | 2022-12-28 |
AU2020376950A1 (en) | 2022-06-09 |
US20240041811A1 (en) | 2024-02-08 |
TW202131910A (zh) | 2021-09-01 |
IL292612A (en) | 2022-07-01 |
US11723890B2 (en) | 2023-08-15 |
CN114786660A (zh) | 2022-07-22 |
WO2021087432A1 (en) | 2021-05-06 |
US20210169835A1 (en) | 2021-06-10 |
CA3156436A1 (en) | 2021-05-06 |
EP4051259A1 (en) | 2022-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020006248A2 (es) | Moduladores de la vía de estrés integrada | |
CO2018012946A2 (es) | Moduladores de la vía de estrés integrada | |
CO2021007993A2 (es) | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina | |
CO2020006227A2 (es) | Moduladores de la vía de estrés integrada | |
UY38685A (es) | Moduladores de la vía de tensión integrada | |
UY37958A (es) | Moduladores de la vía de estrés integrada | |
MX2022010168A (es) | Moduladores de calpainas y usos terapeuticos de los mismos. | |
UY37230A (es) | Moduladores de la vía de estrés integrada | |
ECSP21032861A (es) | Moduladores de profármacos de la vía de estrés integrada | |
UY37231A (es) | Moduladores de la vía de estrés integrada | |
UY37229A (es) | Moduladores de la vía de estrés integrada | |
MX2020004557A (es) | Moduladores de la vía de estrés integrada. | |
BR112019001732A2 (pt) | moduladores de receptor de quimiocina e usos dos mesmos | |
BR112017023365A2 (pt) | composições microbianas e métodos para bioproteção. | |
BR112021019748A2 (pt) | Degradadores de stat e usos dos mesmos | |
PH12020551934A1 (en) | Magl inhibitors | |
UY36322A (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos | |
EA202190708A1 (ru) | Модуляторы экспрессии pnpla3 | |
CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
MX2020002435A (es) | Agentes que modulan las funciones de beta-catenina y sus métodos. | |
BR112017014416A2 (pt) | sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo | |
BR112019003816A2 (pt) | composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição | |
BR112022010143A2 (pt) | Inibidores de ahr e usos respectivos | |
BR112021013174A2 (pt) | Anticorpos anti-cd40 para uso no tratamento da hidradenite supurativa |